We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+0.8%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.76B
AUM Growth
-$301M
Cap. Flow
-$879M
Cap. Flow %
-18.47%
Top 10 Hldgs %
31.51%
Holding
169
New
40
Increased
23
Reduced
18
Closed
45

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$128M
2
BSX icon
Boston Scientific
BSX
+$108M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$89.6M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$76M
5
TOI icon
The Oncology Institute
TOI
+$53.3M

Top Sells

Rank Stock Value
1
NKTX icon
Nkarta
NKTX
+$87.3M
2
SWTX
SpringWorks Therapeutics
SWTX
+$69.3M
3
OSH
Oak Street Health, Inc.
OSH
+$58.2M
4
DFPHU
DFP Healthcare Acquisitions Corp. Unit
DFPHU
+$56.1M
5
DFHTU
Deerfield Healthcare Technology Acquisitions Corp. Unit
DFHTU
+$50.4M

Sector Composition

Rank Sector Weight
1 Healthcare 70.89%
2 Consumer Discretionary 0.23%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBIO
51
DELISTED
Generation Bio
GBIO
$25.6M 0.54%
89,778
-6,344
-7% -$2.03M
BDTX icon
52
Black Diamond Therapeutics
BDTX
$99.1M
$25.4M 0.53%
1,047,599
+245,088
+31% +$6.61M
FATE icon
53
Fate Therapeutics
FATE
$283M
$25.1M 0.53%
+304,000
New +$29.1M
SILK
54
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$24.7M 0.52%
488,545
+375,545
+332% +$20.9M
ADVM
55
DELISTED
Adverum Biotechnologies
ADVM
$23.7M 0.5%
240,444
– –
DCPH
56
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$23.7M 0.5%
528,585
– –
VIVO
57
DELISTED
Meridian Bioscience Inc
VIVO
$23.3M 0.49%
889,269
-1,271,731
-59% -$30.2M
ALEC icon
58
Alector
ALEC
$168M
$21.3M 0.45%
1,055,192
– –
MAACU
59
DELISTED
Montes Archimedes Acquisition Corp. Unit
MAACU
– –
0
– –
BPMC
60
DELISTED
Blueprint Medicines
BPMC
$20.3M 0.43%
+209,000
New +$20.9M
WVE icon
61
Wave Life Sciences
WVE
$1.14B
$19.7M 0.41%
+3,502,970
New +$33.7M
CMRX
62
DELISTED
Chimerix, Inc.
CMRX
$17.5M 0.37%
+1,816,221
New +$16.7M
AMWL icon
63
American Well
AMWL
$185M
$17.2M 0.36%
49,556
+10,000
+25% +$5.42M
ARDX icon
64
Ardelyx
ARDX
$1.25B
$17M 0.36%
2,561,554
– –
CERT icon
65
Certara
CERT
$1.21B
$16.4M 0.34%
600,000
– –
ANNX icon
66
Annexon
ANNX
$841M
$16.3M 0.34%
583,913
-583,913
-50% -$16.1M
MDVL
67
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$16M 0.34%
22,851
– –
PACB icon
68
Pacific Biosciences
PACB
$422M
$15.6M 0.33%
468,000
-107,000
-19% -$3.75M
BVS icon
69
Bioventus
BVS
$843M
$14.6M 0.31%
+957,000
New +$13.6M
RUBY
70
DELISTED
Rubius Therapeutics, Inc
RUBY
$14.6M 0.31%
+550,000
New +$8.03M
BLUE
71
DELISTED
bluebird bio
BLUE
$14.5M 0.3%
+37,079
New +$18.3M
SYK icon
72
Stryker
SYK
$129B
$14.4M 0.3%
59,000
– –
PMVP icon
73
PMV Pharmaceuticals
PMVP
$62.9M
$13.9M 0.29%
423,680
+236,488
+126% +$9.32M
ACHL
74
DELISTED
Achilles Therapeutics
ACHL
$13.2M 0.28%
+800,000
New +$13.2M
CAPAU
75
DELISTED
HighCape Capital Acquisition Corp. Unit
CAPAU
$12.9M 0.27%
1,000,000
– –
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q1 2021 Portfolio in Review

As of Q1 2021, Deerfield Management held 169 positions worth $4.76B, down 6% from $5.06B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Deerfield Management withdrew a net $879M in Q1 2021, closing 45 positions and reducing 18 holdings. Its most notable exit was Nkarta, an estimated $87.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 70% a quarter earlier, followed by Consumer Discretionary and Industrials.

Against the trend, Deerfield Management opened a new position in Edgewise Therapeutics worth $128M.

  • Deerfield Management's largest Q1 2021 buy was Edgewise Therapeutics: 3,933,137 shares worth $128M.
  • Deerfield Management added most to The Oncology Institute in Q1 2021, an estimated $53.3M increase.
  • Deerfield Management's biggest Q1 2021 reduction was SpringWorks Therapeutics, cutting an estimated $69.3M.
  • Deerfield Management fully exited Nkarta in Q1 2021, selling an estimated $87.3M.
  • Deerfield Management's ten largest holdings make up 32% of its $4.76B portfolio in Q1 2021.
  • Deerfield Management opened 40 new positions and closed 45 in Q1 2021.
  • Deerfield Management's portfolio value fell 6% quarter-over-quarter to $4.76B.

Based on Deerfield Management's 13F filing for Q1 2021, filed 17 May 2021.